Anti-BCMA Therapy Endorsed, despite Eye Toxicity.

Article Details

Citation
Copy to clipboard

Authors unspecified

Anti-BCMA Therapy Endorsed, despite Eye Toxicity.

Cancer Discov. 2020 Aug 5. pii: 2159-8290.CD-NB2020-074. doi: 10.1158/2159-8290.CD-NB2020-074.

PubMed ID
32759303 [ View in PubMed
]
Abstract

An FDA advisory committee recommended approval of belantamab mafodotin, a first-in-class BCMA-targeted therapy, to treat patients with multiple myeloma refractory to several other drugs. Agency officials had raised concerns about the high incidence of corneal disease linked to the therapy, but clinical experts felt that the demonstrated benefits outweighed the risks of ocular toxicity.

DrugBank Data that Cites this Article

Drugs